JUL 04, 2018 12:01 AM PDT

Discovery of New Properties of an Anti-Tuberculosis Drug

WRITTEN BY: Nouran Amin

 

Investigators at the University of Otago found novel properties of a new anti-tuberculosis drug which may inspire more new drugs to treat tuberculosis.

Tuberculosis (TB), as well as TB resistant drugs, are responsible for about 1.7 million global deaths per year.

In a collaboration, Greg Cook a professor at the Department of Microbiology and Immunology from the University of Otago and postdoctoral fellow Kiel Hards, have been studying one of the first recent TB drugs to be approved in decades. This anti-tuberculosis drug is called Bedaquiline and is sold under the brand name Sirturo.

"Bedaquiline is the first new drug to be developed after 40 years of searching for more effective drugs that combat TB and was only FDA (US Food and Drug Administration) approved in 2012," explains Greg Cook. "But one drug won't be enough to reverse a 40-year lull in drug-development, so our lab is actively searching for new TB drugs to complement Bedaquiline and expand the treatment options available to clinicians worldwide."

In fact, to create drugs that are strong enough to fight TB, the effective properties of Bedaquiline must be examined in detail.

"The most promising aspects of the drug are its ability to shorten treatment timeframe to eight weeks and that its target is unconventional for an antimicrobial. Bedaquiline disrupts the ability of M. tuberculosis to generate energy," explains Hard. "What we discovered is that the drug has a second activity or property that may explain how it is able to kill non-replicating cells. This second activity (termed ionophoric) involves the movement or shutting of ions across the mycobacterial membrane resulting in the dissipating of critical ion gradients needed for growth and survival."

Professor Cook believes that their research findings published in the international journal Proceedings of the National Academy of Sciences may have ramifications for other antibiotics.

"We believe that we can design more effective TB drugs if we include ionophore-like properties in a similar way to Bedaquiline," he says. "The 'biological electricity' that these ions normally create is key to energy generation and a whole series of other incredibly important cellular processes. It was already known that disrupting these ion gradients is lethal to M. tuberculosis but before Bedaquiline there were no drugs that could do this and be safe in humans."

Discovering novel properties of drugs are rare, noted by Professor Cook, because scientists usually focus on the main purpose or target of a drug which often allow them to ignore the secondary effects.

"Subsequent discoveries are usually serendipitous, but in the case of Bedaquiline we realized the previous data didn't explain how it could kill non-replicating cells and so we kept pushing to find the answer," says Cook. "Many researchers are now turning their attention back to focusing on how antimicrobials actually kill bacteria to uncover new pathways of cell death. These offer tremendous potential to develop new antimicrobials."

Source: Proceedings of the National Academy of Sciences, Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 06, 2020
Cardiology
A New Heart Drug Taken from a Yellow Dye
OCT 06, 2020
A New Heart Drug Taken from a Yellow Dye
Cardiovascular disease is an ever-present issue in the modern world.  One of the most unfortunate cardiovascular ev ...
NOV 02, 2020
Cancer
Using an Anti-Malarial Drug to Fight Cancer
NOV 02, 2020
Using an Anti-Malarial Drug to Fight Cancer
Modern pharmaceutical companies spend billions of dollars and years of time developing the next big drug. What if they d ...
NOV 01, 2020
Cannabis Sciences
Can Cannabis Treat ALS?
NOV 01, 2020
Can Cannabis Treat ALS?
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative illness that damages motor neurons and leads to progressive m ...
NOV 08, 2020
Cell & Molecular Biology
Mouth Spray for Epidermolysis Bullosa in Development
NOV 08, 2020
Mouth Spray for Epidermolysis Bullosa in Development
Epidermolysis Bullosa (EB) is a rare genetic disorder that makes the skin incredibly fragile; it forms blisters and can ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
Loading Comments...